指南与共识卫生政策与健康促进免疫规划

英国疫苗成本效果评估方法修订:卫生部磋商见解

Appraising the cost-effectiveness of vaccines in the UK: Insights from the Department of Health Consultation on the revision of methods guidelines.
指南 / 共识 · Vaccine · 2019-04-15

本文评述英国卫生部及社会关怀部就修订疫苗成本效果评估方法开展的磋商,重点审视JCVI现行方法及27条建议,认为整体合理,但指出11条建议需进一步讨论或重新考虑,尤其质疑将贴现率从3.5%降至1.5%的依据,并认为不确定分析方面的方法需修订。

要点

  • 磋商提出27条方法修订建议,整体被视为合理且审慎。
  • 11条建议需进一步评论或重新考虑。
  • 将贴现率从3.5%降至1.5%的依据受到质疑。

核心结论

  • 磋商提出的27条建议整体体现合理审慎的方法改革思路,但其中11条需进一步评论或重新考虑。
  • 将贴现率从3.5%降至1.5%的依据值得质疑。
  • 疫苗成本效果不确定性分析方法需修订,且贴现与不确定性分析建议在经济理论、实证依据及与NICE方法一致性方面存在不足。

研究设计与样本

  • 本文为对英国卫生部及社会关怀部关于修订疫苗成本效果评估方法磋商的评述性文章,系统审视JCVI现行方法及27条修订建议。

主要发现

  • 磋商共提出27条方法修订建议。
  • 作者识别出11条值得进一步评论或重新考虑的建议。
  • 作者质疑将贴现率从3.5%降至1.5%的依据。
  • 作者认为疫苗成本效果不确定性分析的现行方法部分需修订。
  • 贴现与不确定性分析建议被认为在经济理论、实证依据及与NICE方法一致性方面存在不足。

关键数值与推荐

  • 磋商建议将贴现率从3.5%降至1.5%。
  • 磋商共提出27条方法修订建议,其中11条被作者认为需进一步评论或重新考虑。

临床怎么用

  • 提示疫苗经济性评估方法改革需关注贴现率选择与不确定性分析的理论与实证依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The UK Department of Health and Social Care recently held a consultation on proposals to revise the methods for the appraisal of cost-effectiveness of vaccines as applied by the Joint Committee on Vaccination and Immunisation (JCVI). This presents a useful opportunity to review the current methods applied by the JCVI and examine the proposals for their improvement. Reviewing such methods is timely as there is mounting evidence that key elements of the health economic appraisal of all healthcare interventions in the UK need to be revised. In particular, there is a need to reassess both the cost-effectiveness threshold used to judge if an intervention is cost-effective and the discount rates used to assess the present value of health gains that occur in the future. Accordingly, we critically appraise the methods and their proposed changes. Overall, the 27 recommendations made within the recent consultation on proposed changes indicate a sensible and carefully considered approach to methods reform. We identify 11 recommendations that deserve further comment or reconsideration. In particular, there are reasons to question the basis for the proposed reduction of the discount rate from 3.5% to 1.5%. We also find that aspects of the current methods for considering uncertainty in the cost-effectiveness of vaccines require revision. Both the discounting and uncertainty analyses recommendations do not appear to be well grounded in economic theory, empirically justified or consistent with the methods set out by the National Institute for Health and Care Excellence.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. O'Mahony JF, Paulden M. Appraising the cost-effectiveness of vaccines in the UK: Insights from the Department of Health Consultation on the revision of methods guidelines. Vaccine. 2019. PMID: 31000411. doi:10.1016/j.vaccine.2019.03.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。